140 related articles for article (PubMed ID: 37984242)
61. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
62. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
[TBL] [Abstract][Full Text] [Related]
63. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
64. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.
Rau TT; Bettschen E; Büchi C; Christe L; Rohner A; Müller MD; Carlson JW; Imboden S; Zlobec I
Mod Pathol; 2021 Jan; 34(1):222-232. PubMed ID: 32728223
[TBL] [Abstract][Full Text] [Related]
65. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
[TBL] [Abstract][Full Text] [Related]
66. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
[TBL] [Abstract][Full Text] [Related]
67. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas.
Pain FA; Beinse G; Azaïs H; Auvray-Kuentz M; Garcin LM; Delanoy N; Bentivegna E; Benoit L; Nguyen-Xuan HT; Blons H; Fabiano E; LE Frère Belda MA; Bats AS; Koual M
Eur J Surg Oncol; 2023 Sep; 49(9):106954. PubMed ID: 37349159
[TBL] [Abstract][Full Text] [Related]
68. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
Casey L; Singh N
Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
[TBL] [Abstract][Full Text] [Related]
69.
De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
[TBL] [Abstract][Full Text] [Related]
70. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer.
Jamieson A; Bosse T; McAlpine JN
Ther Adv Med Oncol; 2021; 13():17588359211035959. PubMed ID: 34408794
[TBL] [Abstract][Full Text] [Related]
71. New staging of endometrial carcinoma - FIGO 2023.
Hruda M; Sehnal B; Halaška MJ; Drozenová J; Robová H; Pichlík T; Rob L
Ceska Gynekol; 2024; 89(2):120-127. PubMed ID: 38704224
[TBL] [Abstract][Full Text] [Related]
72. Predicting the Risk of nOdal disease with histological and Molecular features in Endometrial cancer: the prospective PROME trial.
Bogani G; Lalli L; Casarin J; Ghezzi F; Chiappa V; Fanfani F; Scambia G; Raspagliesi F
Int J Gynecol Cancer; 2024 Apr; ():. PubMed ID: 38658017
[TBL] [Abstract][Full Text] [Related]
73. Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics.
Huvila J; Jamieson A; Pors J; Hoang L; Mirkovic J; Cochrane D; McAlpine JN; Gilks CB
Int J Gynecol Pathol; 2024 Feb; ():. PubMed ID: 38303106
[TBL] [Abstract][Full Text] [Related]
74. Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence.
Ran X; Hu T; Li Z
Front Oncol; 2022; 12():810631. PubMed ID: 35664732
[TBL] [Abstract][Full Text] [Related]
75. Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
Bidzinski M; Danska-Bidzinska A; Rychlik A; Kypryjanczyk J; Pyzlak M; Piatek S
Ginekol Pol; 2022; 93(2):163-167. PubMed ID: 35072255
[TBL] [Abstract][Full Text] [Related]
76. The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning.
Fremond S; Koelzer VH; Horeweg N; Bosse T
Front Oncol; 2022; 12():928977. PubMed ID: 36059702
[TBL] [Abstract][Full Text] [Related]
77. Clear cell carcinoma of the endometrium.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Lorusso D; Coleman R; Vaughan MM; Takano M; Provencher D; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Kim JW; Candido Dos Reis FJ; Mariani A; Leitao MM; Makker V; Rustum NA; Vergote I; Zannoni GF; Tan DSP; McCormack M; Bini M; Lopez S; Raspagliesi F; Panici PB; di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2022 Mar; 164(3):658-666. PubMed ID: 35063279
[TBL] [Abstract][Full Text] [Related]
78. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
[TBL] [Abstract][Full Text] [Related]
79. Where Morphological and Molecular Classifications Meet: The Role of p53 Immunohistochemistry in the Prognosis of Low-Risk Endometrial Carcinoma (GLAMOUR Study).
Puppo A; Fraternali Orcioni G; Clignon V; Musizzano Y; Zavattero CA; Vocino Trucco G; Benazzo GM; Vizzielli G; Restaino S; Mariuzzi L; Orsaria M; Seracchioli R; Raimondo D; Bertoldo L; Uccella S; Caliò A; Vittori Antisari G; Garzon S; Capozzi VA; Berretta R; Cosentino F; Ercoli A; Ieni A; Arcieri M; Ceccaroni M; Pesci A; Mantovani G; Bruni F; Roviglione G; Zeppa P; Raffone A; Camanni M; Delpiano EM; Provenza C; Borghese M; Migliaretti G
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539423
[TBL] [Abstract][Full Text] [Related]
80. Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux KA; Weiel JJ; Pors J; Steiner DF; Ho C; Charu V; Suarez CJ; Renz M; Diver E; Karam A; Litkouhi B; Dorigo O; Kidd EA; Yang EJ; Folkins AK; Longacre TA; Howitt BE
Mod Pathol; 2022 May; 35(5):688-696. PubMed ID: 34743187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
